BioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 11.4% in December

BioAtla, Inc. (NASDAQ:BCAB) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 4,400,000 shares, a growth of 11.4% from the December 15th total of 3,950,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the short-interest ratio is presently 3.9 days.

BioAtla Trading Up 1.5 %

Shares of BCAB stock traded up $0.01 during trading on Friday, reaching $0.49. 373,650 shares of the company’s stock traded hands, compared to its average volume of 1,483,387. The firm’s 50-day moving average is $1.17 and its 200 day moving average is $1.57. BioAtla has a 1 year low of $0.45 and a 1 year high of $4.02. The company has a market capitalization of $23.84 million, a P/E ratio of -0.29 and a beta of 1.17.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.12. The company had revenue of $11.00 million during the quarter. During the same period in the prior year, the firm earned ($0.70) earnings per share. As a group, sell-side analysts predict that BioAtla will post -1.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright lowered BioAtla from a “buy” rating to a “neutral” rating in a report on Wednesday, November 13th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in shares of BioAtla in the second quarter valued at approximately $872,000. Scion Asset Management LLC purchased a new stake in BioAtla in the 2nd quarter worth approximately $869,000. GSA Capital Partners LLP bought a new position in BioAtla in the 3rd quarter valued at $623,000. Bank of Montreal Can grew its position in shares of BioAtla by 55.1% during the 2nd quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock valued at $554,000 after purchasing an additional 143,521 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of BioAtla by 36.1% in the second quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock worth $59,000 after purchasing an additional 11,503 shares during the period. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.